JOURNAL OF SUBSTANCE ABUSE TREATMENT, published by Pergamon-Elsevier Science Ltd, is a leading peer-reviewed journal that spans a wide range of topics related to substance abuse and addiction treatments. With an impressive impact factor, this esteemed journal ranks in the Q1 quartile across multiple disciplines including Clinical Psychology, Medicine (miscellaneous), and Psychiatry and Mental Health, making it a vital resource for researchers and practitioners alike. Covering convergence years from 1984 to 2023, it publishes cutting-edge research that informs treatment methodologies and policy development in the field of substance abuse. With access options that adapt to both traditional and modern academic needs, the journal seeks to advance the understanding and effectiveness of substance abuse treatment through comprehensive studies and innovative approaches. Be part of a global dialogue that shapes the future of addiction treatment by engaging with the latest findings and expert analyses that help bridge the gap between research and clinical practice.

Canadian Journal of Addiction is a leading platform dedicated to advancing the understanding of addiction and its multifaceted impacts on individuals and society. Published by LIPPINCOTT WILLIAMS & WILKINS, this journal aims to foster rigorous research and discussion in the field of addiction studies, contributing significantly to the intersection of psychiatry and mental health. With its ISSN 2368-4720 and E-ISSN 2368-4739, the journal is indexed in Scopus and has been categorized in the Q3 quartile for 2023, reflecting its emerging influence amongst peers. The Canadian Journal of Addiction facilitates a vital exchange of ideas and findings, crucial for researchers, practitioners, and students alike, addressing pressing issues related to addiction through innovative studies and insightful reviews. Subscribers and readers benefit from the latest findings as they navigate through the dynamic landscape of addiction research, enriching both academic knowledge and practical applications.

Middle East Current Psychiatry (MECPsych), published by SpringerNature, is a prominent open-access journal dedicated to advancing the field of psychiatry and mental health in the Middle East and beyond. Since its establishment in 2011, MECPsych has aimed to disseminate high-quality research, reviews, and reports that capture recent developments in psychiatric science, clinical practice, and public health considerations in mental well-being. With an impact factor reflective of its growing influence and classified in the Q3 quartile for Psychiatry and Mental Health, the journal offers invaluable insights backed by rigorous peer review processes. Operating under an open access model since 2019, MECPsych ensures that its articles are freely accessible to a global readership, enhancing the visibility and application of research findings. As part of its ongoing commitment to enriching understanding in the field, MECPsych also encourages submissions that explore the unique cultural, societal, and economic factors influencing mental health across the region. This approach not only supports researchers, professionals, and students in their pursuit of knowledge but also fosters a collaborative dialogue among mental health stakeholders in the Middle East and around the world.

Substance Abuse is a premier scholarly journal published by SAGE Publications Inc, dedicated to advancing the understanding and treatment of substance use disorders. With an established presence from 1995 to 2023, the journal boasts an impressive Q1 ranking in both Medicine (miscellaneous) and Psychiatry and Mental Health, positioning it among the top tier of academic publications in these fields. Researchers and professionals will find its articles, which are grounded in rigorous empirical studies and innovative interventions, essential for addressing the complex and multifaceted nature of substance abuse. Although not an open access publication, Substance Abuse maintains a commitment to sharing valuable insights and findings, making it a vital resource for those looking to enhance their knowledge and practice. Located in Thousand Oaks, CA, this journal serves as a critical forum for international dialogue and research dissemination, ensuring that current trends and challenges in substance use are thoughtfully examined and discussed within the academic community.

Advances in Dual Diagnosis, published by EMERALD GROUP PUBLISHING LTD, serves as a vital resource for professionals and researchers in the fields of psychiatry and mental health. With an ISSN of 1757-0972 and E-ISSN 2042-8324, this journal has been at the forefront of dual diagnosis research since its inception in 2008, aiming to bridge the gap in knowledge and practice regarding the co-occurrence of mental health disorders and substance use issues. Rated in the Q4 category for Psychiatry and Mental Health, it ranks 31st out of 45 in Nursing and Psychiatric Mental Health and 408th out of 567 in Medicine and Psychiatry, providing a unique platform for showcasing emerging research, innovative treatment strategies, and case studies that enhance understanding of complex patient needs. While the journal is not openly accessible, its contributions are crucial for driving forward the academic discourse and practical applications surrounding dual diagnosis. As we look to the future through 2024 and beyond, the Advances in Dual Diagnosis journal continues to strive for excellence in disseminating knowledge that benefits practitioners and scholars alike.

DRUG AND ALCOHOL REVIEW, published by Wiley, is a leading journal dedicated to advancing the scholarship in the fields of drug and alcohol research. Since its inception in 1989, this esteemed publication has provided a critical platform for the dissemination of innovative research findings, reviews, and theoretical papers, addressing pressing issues in substance use and addiction. With an impact factor that places it in the Q1 category in both Health (social science) and Medicine (miscellaneous), it ranks #78 out of 371 in the Scopus index for Health and #115 out of 398 in Medicine, reflecting its significant influence and high citation rates among scholars. The journal is committed to fostering a multidisciplinary approach, integrating perspectives from psychology, sociology, public health, and medicine, to inform policy and practice. Accessible to researchers and practitioners alike, *DRUG AND ALCOHOL REVIEW* serves as an essential resource for anyone invested in understanding and addressing the complexities of drug and alcohol use in society.

Annals of Clinical Psychiatry, published by QUADRANT HEALTHCOM INC, is a leading journal in the fields of Medicine and Psychiatry & Mental Health. With its longstanding commitment to advancing clinical knowledge since 1989, this esteemed journal contributes invaluable insights into current psychiatric practices and mental health research. The journal is recognized in the Scopus ranking with a position in the 34th percentile, reflective of its focused scope and substantial academic contributions. While access to the journal is tailored for professionals and researchers, the absence of Open Access highlights the journal's dedication to maintaining quality and rigorous peer-reviewed standards. As part of the Q3 quartile for both Medicine and Psychiatry categories in 2023, Annals of Clinical Psychiatry serves as an essential resource for those dedicated to improving mental health outcomes, making it a vital platform for practitioners, researchers, and students alike. Situated in Parsippany, New Jersey, the journal remains a pivotal entity that fosters scholarly dialogue and exploration in clinical psychiatry.

Rivista di Psichiatria, published by PENSIERO SCIENTIFICO EDITORE, stands as a significant contributor to the field of Psychiatry and Mental Health since its inception in 1975. With an ISSN of 0035-6484 and an E-ISSN of 2038-2502, this esteemed journal offers a platform for rigorous academic discourse and cutting-edge research, helping to shape contemporary psychiatric practices and theories. Currently holding a Q2 designation in Psychiatry and Mental Health based on the 2023 category quartiles, and ranking #197 out of 567 in Scopus, it reflects a commendable 65th percentile among its peers. The journal welcomes contributions that encompass a broad range of topics related to mental health, encouraging contributions from a multidisciplinary approach, which aids in its goal of advancing the understanding and application of psychiatric science. While it is a traditional journal without Open Access options, access to its valuable content can support researchers, clinicians, and students in their pursuit of knowledge and innovation within the field. Situated in Rome, Italy, at VIA SAN GIOVANNI VALDARNO 8, ROME 00138, the journal continues to enhance its rich legacy, promoting the exchange of ideas and fostering collaboration amongst practitioners and scholars alike.

Substance Abuse Treatment, Prevention, and Policy is a premier open access journal published by BMC, dedicated to advancing the understanding and improvement of substance abuse treatment and prevention strategies. Since its inception in 2006, this journal has established itself as a significant resource in the fields of Health Policy and Psychiatry and Mental Health, proudly maintaining a strong reputation reflected in its 2023 Scopus rankings, which place it in the top quartiles of these categories. With an impactful focus on policy implications and evidence-based practices, the journal's comprehensive coverage supports the sharing of innovative research and perspectives aimed at mitigating substance abuse challenges worldwide. Open access since its launch, it ensures that vital research is readily available to researchers, practitioners, and students alike, facilitating collaboration and discourse in this critical area of public health. Its commitment to high-quality research is underscored by its rankings within the 78th percentile for Health Policy and 66th percentile for Psychiatry and Mental Health, highlighting its influence and relevance in addressing pressing issues in substance misuse.

JOURNAL OF ADDICTIVE DISEASES, published by ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD, serves as a pivotal platform for researchers, clinicians, and students in the realms of clinical psychology, psychiatry, and addiction studies. With a distinguished history dating back to its inception in 1991, this journal spans critical research developments with its current scope covering converged years from 2018 to 2024, ensuring a robust repository of knowledge. Notably, it holds a respectable impact factor and is categorized in Q2 quartiles across several disciplines including Clinical Psychology, Medicine (miscellaneous), and Psychiatry and Mental Health for 2023, reflecting its impactful contributions to the scientific community. Despite the journal not currently offering Open Access, it remains highly ranked, occupying positions in the top percentiles of Scopus rankings. This journal emphasizes the importance of disseminating high-quality research focused on addictive behaviors and diseases, thereby addressing vital clinical and public health challenges.